Caribou Biosciences (NASDAQ: CRBU) reported strong Phase 1 efficacy data for its allogeneic CAR-T candidate in large B-cell lymphoma, prompting BofA Securities to reaffirm its Buy rating and $6.00 price target.

Key Highlights

  • Vispa-cel achieved an overall response rate exceeding four-fifths of evaluable patients with a median progression-free survival of more than 17 months in the ANTLER Phase 1 trial.
  • BofA Securities reaffirmed a Buy rating and $6.00 price target on CRBU, citing significant valuation upside following the EHA 2026 Annual Meeting data presentation.

Caribou Biosciences (NASDAQ: CRBU) presented updated results from the ANTLER Phase 1 trial of vispa-cel at the European Hematology Association 2026 Annual Meeting, delivering efficacy data that reinforces the company's position as a leading allogeneic CAR-T stock in the clinical-stage biotech sector.

The trial evaluated vispa-cel as a second-line treatment in large B-cell lymphoma, a common and aggressive blood cancer. An overall response rate exceeding four-fifths of patients, combined with a median progression-free survival of more than 17 months, places vispa-cel among the strongest performers reported in this treatment setting for an off-the-shelf cell therapy.

The safety profile observed was compatible with outpatient administration, a meaningful clinical differentiator in cell therapy. Most approved autologous CAR-T products require inpatient monitoring during infusion, adding logistical burden and cost for patients and healthcare systems alike.

BofA Securities responded to the data by reaffirming its Buy rating and $6.00 price target on CRBU stock, pointing to significant valuation upside for investors willing to look past near-term binary risk. The reiteration from a major Wall Street institution adds institutional credibility to the investment case at a pivotal clinical moment.

For investors tracking best allogeneic CAR-T stocks in 2026, CRBU represents one of the most clinically advanced off-the-shelf platforms in the hematology space. Allogeneic therapies use donor cells manufactured in advance, eliminating the weeks-long personalised manufacturing process required for autologous products.

Caribou Biosciences also disclosed regulatory clearance for the ANTLER-3 Phase 3 trial, the pivotal study that would support a potential approval filing for vispa-cel. With a cash runway extending into late 2027, the company has operational capacity to initiate and advance the Phase 3 programme without requiring near-term capital raises.

CRBU stock has attracted growing attention from investors in CAR-T therapy stocks and clinical-stage oncology biotechs, particularly following the dual data readout at EHA 2026. The combination of strong Phase 1 efficacy, a favourable safety profile, and a funded path to Phase 3 positions Caribou as a key name to watch in the second half of 2026.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.